The pharmaceutical industry is preparing for a significant compliance challenge as US regulators move closer to implementing expanded reporting requirements for per- and polyfluoroalkyl substances (PFAS).
Often referred to as "forever chemicals," PFAS have become one of the most heavily scrutinized chemical categories in global regulatory policy. While much of the public discussion has focused on consumer products and environmental concerns, pharmaceutical manufacturers are increasingly finding themselves within the scope of new reporting and disclosure obligations.
For compliance, procurement and quality assurance teams, 2026 may become a pivotal year for PFAS supply chain management.
Why PFAS Regulations Matter to Pharmaceutical Companies
PFAS are a broad family of fluorinated chemicals valued for properties such as:
Chemical resistance
Heat resistance
Low surface energy
Water repellency
Oil resistance
These characteristics have led to their use across numerous industrial applications, including pharmaceutical manufacturing.
Potential touchpoints include:
Processing aids
Equipment coatings
Packaging materials
Specialized films
Fluorinated polymers
Certain manufacturing components
Many companies may not intentionally purchase PFAS as a raw material, yet still encounter them somewhere within their supply chains.
This is precisely why regulatory agencies are expanding reporting requirements.
Understanding the New Reporting Framework
The upcoming reporting obligations are expected to focus on PFAS substances manufactured or imported into the United States over an extended historical period.
The objective is to create a more complete understanding of:
PFAS production volumes
Import activity
Industrial uses
Downstream applications
Supply chain exposure
For pharmaceutical organizations, this means visibility across the entire value chain will become increasingly important.
Compliance efforts will likely extend far beyond direct suppliers.
Why Multi-Tier Supply Chain Visibility Matters
One of the biggest challenges associated with PFAS compliance is that exposure often exists several tiers removed from the finished product manufacturer.
For example, PFAS may appear in:
Raw material processing
Intermediate manufacturing
Packaging components
Logistics materials
Equipment systems
As a result, compliance teams must move beyond first-tier supplier questionnaires and develop deeper supply chain visibility.
Organizations that rely solely on direct supplier declarations may overlook important risk areas.
The Minnesota Deadline Adds Additional Pressure
Federal reporting obligations are not the only issue facing pharmaceutical companies.
State-level PFAS regulations are also expanding.
Minnesota's PFAS legislation introduces additional compliance considerations and reporting requirements, creating another important deadline for manufacturers and suppliers.
For companies selling into multiple US markets, regulatory complexity is increasing rapidly.
This trend highlights the importance of developing comprehensive PFAS management programs rather than treating individual regulations as isolated events.
Areas of Potential Exposure
Pharmaceutical manufacturers should evaluate several areas of possible PFAS exposure.
Ingredients and Excipients
Although many pharmaceutical ingredients do not contain PFAS, supplier verification remains essential.
Questions should include:
Are fluorinated compounds present?
Are PFAS used during production?
Are PFAS-containing processing aids involved?
Packaging Materials
Packaging has become a major focus area for regulators.
Potential exposure points include:
Coatings
Barrier materials
Laminates
Specialty films
Manufacturing Equipment
Some fluorinated materials are used in equipment components because of their chemical resistance.
Examples may include:
Seals
Tubing
Liners
Gaskets
Contract Manufacturing Operations
CDMOs and third-party suppliers should also be included in compliance assessments.
A complete risk review must consider the entire manufacturing network.
Why Procurement Teams Are Becoming Central to Compliance
Historically, PFAS compliance might have been viewed primarily as an environmental or regulatory issue.
That perspective is changing.
Today, procurement teams play a critical role because supplier information forms the foundation of compliance programs.
Responsibilities increasingly include:
Supplier screening
Documentation collection
Material declarations
Risk assessments
Contractual compliance requirements
In many organizations, procurement has become the first line of defense against supply chain compliance risks.
Building a PFAS Assessment Program
Leading pharmaceutical companies are implementing structured approaches to PFAS management.
Key elements often include:
Supplier Mapping
Identify all relevant suppliers and manufacturing locations.
Material Reviews
Evaluate ingredients, excipients and packaging components.
Documentation Collection
Request declarations, certifications and supporting technical information.
Risk Classification
Prioritize suppliers based on potential PFAS exposure.
Ongoing Monitoring
Establish processes for future regulatory changes and supplier updates.
The earlier these programs begin, the easier compliance becomes.
Potential Business Impacts
The consequences of inadequate preparation may include:
Regulatory reporting challenges
Increased compliance costs
Product reformulation requirements
Supplier replacement efforts
Market access risks
Conversely, companies that establish strong compliance systems may gain advantages through:
Better supplier visibility
Reduced regulatory risk
Faster reporting capability
Improved customer confidence
What Pharma Companies Should Do Before Mid-2026
Several practical steps can help organizations prepare.
Conduct Supplier Surveys
Begin collecting PFAS-related information from suppliers immediately.
Review Packaging Components
Evaluate all packaging materials for potential fluorinated substances.
Engage Contract Manufacturers
Ensure CDMOs understand upcoming compliance expectations.
Establish Internal Governance
Define ownership across procurement, regulatory affairs and quality teams.
Create Documentation Systems
Centralized recordkeeping will simplify future reporting requirements.
Companies that wait until reporting deadlines approach may face significant administrative burdens.
The Bottom Line
PFAS regulation is rapidly becoming a major compliance issue across the pharmaceutical industry. As reporting requirements expand and state-level regulations continue evolving, pharmaceutical manufacturers must develop a clear understanding of where PFAS may exist within ingredients, excipients, packaging materials and manufacturing processes.
The organizations best prepared for 2026 will be those that begin building supply chain visibility now. Comprehensive supplier assessments, robust documentation programs and proactive procurement engagement will be essential for navigating the next phase of PFAS compliance.
For pharmaceutical companies, PFAS is no longer simply an environmental issue—it is becoming a core supply chain governance and regulatory risk management priority.
Acrylic Acid (Glacial) - China CAS: 79-10-7
